AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02203045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Study NCT04809298 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Free-hand therapeutic CT-guided punction for lumbar pain
Description: Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
Study NCT04809298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puncture Cube
Description: Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
Study NCT02661490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
Study NCT02661490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride (saline)
Description: norovirus bivalent placebo-matching vaccine
Study NCT02661490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
Study NCT02600897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
Study NCT02140450 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Artificial tears, 2 drops, 1-2 hours before intravitreal injection
Study NCT05329636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant (FMT)
Description: FMT through capsules- patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen capsules on two consecutive days.
Study NCT05329636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Patients will evacuate the bowel with 1 liter of Meroken solution 12 hours prior to the procedure and will fast from food for 12 hours prior to the procedure. Patients will swallow 30 frozen placebo-capsules on two consecutive days.
Study NCT05329636 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Auto Fecal Microbial Transplant (FMT) via enema
Description: 3.FMT through enema- patients will evacuate the bowel prior to the procedure and will fast for 3 hours prior to the procedure . Patients will receive 80 ml of enema. Enemas will be administered with the assistance of the study nurse. Patients will be asked to hold the enema content for at least 15 minutes.
Study NCT01800565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of LH in first-voided urine
Description: participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
Study NCT01800565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection of first-voided urine sample for LH level
Description: participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
Study NCT01711021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-Amphetamine Transdermal Patch
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Study NCT01711021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Study NCT01867242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes
Description: Smoke their usual brand of cigarettes and follow their normal patterns of use.
Study NCT01867242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus
Description: Winterchill or Robust flavors
Study NCT01075763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
Study NCT01075763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
Study NCT01584661 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary recommendations
Study NCT02129023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbox 360
Description: For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
Study NCT00678392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: axitinib will be given at a starting dose of 5 mg twice daily \[BID\] with continuous dosing
Study NCT00678392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib will be given at a dose of 400 mg twice daily \[BID\] with continuous dosing
Study NCT01717898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
Study NCT01717898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
Study NCT01717898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
Study NCT02371798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Description: IV administration of 0.2 mmol/kg of Gd-DTPA
Study NCT03175120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Study NCT03175120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Study NCT04076358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tab-CBI
Description: Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
Study NCT02180308 — intervention group
Intervention type: DEVICE
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study NCT02419677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance.
Study NCT02419677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance.
Study NCT02419677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study NCT00685724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
Study NCT02507375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered as oral tablets.
Study NCT01337466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: This is a single dose study of 2 mCi \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
Study NCT05033262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Our Memory Care Wishes
Description: Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
Study NCT02600897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
Study NCT02600897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
Study NCT02600897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Study NCT02126267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
Study NCT05242913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Potato Starch
Description: Unmodified potato starch containing >60% resistant starch Type 2
Study NCT03153410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study NCT03153410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine (GVAX)
Description: 5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study NCT03153410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study NCT03153410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-CS4
Description: 75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study NCT02126267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth disinfection
Description: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
Study NCT02507375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as intravenous (IV) infusion.
Study NCT02126267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel and gluconate
Description: application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
Study NCT02126267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
Study NCT01060592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP device (FDA Device Listing Number : D091203)
Description: The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
Study NCT01290939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT02126267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg) once daily for 3 consecutive days.
Study NCT02422966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT02422966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT00976820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections
Study NCT00976820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections
Study NCT01290939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide Placebo
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide Placebo
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH (agonist)
Study NCT01290939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Study NCT04321356 — intervention group
Intervention type: DEVICE
Intervention: Triathlon PCR TKA
Description: Total Knee Arthroplasty System
Study NCT02531516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH (agonist)
Study NCT04321356 — intervention group
Intervention type: DEVICE
Intervention: Triathlon PS TKA
Description: Total Knee Arthroplasty System
Study NCT04321356 — intervention group
Intervention type: DEVICE
Intervention: Persona PCR TKA
Description: Total Knee Arthroplasty System
Study NCT04321356 — intervention group
Intervention type: DEVICE
Intervention: Persona PS TKA
Description: Total Knee Arthroplasty System
Study NCT02531516 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 74-80 Grays (units of radiation)
Study NCT02531516 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 74-80 Grays (units of radiation)
Study NCT03443388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hövding inflatable helmet
Description: The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
Study NCT04599192 — intervention group
Intervention type: OTHER
Intervention: No study intervention
Description: The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
Study NCT01252563 — intervention group
Intervention type: DRUG
Intervention: Amlodipine
Description: Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
Study NCT05242913 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fully digestible corn starch
Study NCT00946998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
Study NCT00946998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet will be identical and matched to sertraline tablet.
Study NCT02055053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Bupivicaine
Description: Local anesthetic
Study NCT02055053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Bupivicaine
Description: Local anesthetic
Study NCT01143298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847 oral solution
Study NCT03609931 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral Valve Model
Description: Creation of a mitral valve patient specific model to see if it mimics the patients valve
Study NCT04080843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
Study NCT04080843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
Study NCT04080843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2,D1
Study NCT00621166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: generic lopinavir/ritonavir
Description: Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional.
Study NCT00235014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril
Description: 2 mg QD